The lab is particularly skilled at implanting patient tumor cells into the CAM of the avian embryo.  In these images, we’ve taken an RCC patient’s tumor cells, cultured and expanded them, transduced them to express GFP and then implanted them into the CAM.  We also implant patient biopsies too but these don’t get transduced with LV-GFP.  We use this model because the CAM is highly angiogenic and we can evaluate anti-angiogenesis drugs to match the patient with the best drug/targeted therapy.  Dr. Nicholas Power (partner in crime) leads these efforts and his goal is to be able to offer the best drug (Sunitinib, Pazopanib, etc.) to his patient prior to drug administration.  This will hopefully minimize drug resistance and extend patient overall survival.